News Releases

• 03 Aug 2009 Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 (Tovok™) as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
• 15 May 2009Boehringer Ingelheim to present new phase II clinical data on two lead oncology compounds at ASCO 2009
• 17 November 2008First pivotal trials begin for Boehringer Ingelheim's novel triple angiokinase inhibitor Vargatef
• 22 October 2008Boehringer Ingelheim broadens oncology pipeline with promising new data for potentially first in class Plk1 inhibito
• 25 April 2008Data suggests promising overall survival and progression-free survival with Vargatef™ (BIBF 1120)
• news release archive

Documents

Information about cancer
• Backgrounder: Cancer - an overview - PDF (176 KB)
• Fact Sheet: The global burden of cancer - PDF (98 KB)
• Backgrounder: Lung cancer - PDF (115 KB)
• Backgrounder: Ovarian cancer - PDF (100 KB)

Compound information
• Fact Sheet: Tovok^TM (BIBW 2992) - PDF (115 KB)
• Fact Sheet: Vargatef^TM (BIBF 1120) - PDF (111 KB)
• Backgrounder: Targeted therapies - PDF (134 KB)

Further oncology information
• Backgrounder: Boehringer Ingelheim in oncology - PDF (133 KB)
• Fact Sheet: Boehringer Ingelheim R&D in oncology - PDF (100 KB)
• Backgrounder: Personalised medicine - PDF (107 KB)
• Backgrounder: Glossary of Terms - PDF (132 KB)

Related Information
• Boehringer Ingelheim's Progress in Oncology

• Media bulletin: Boehringer Ingelheim Oncology Progress Report - May 2008 - PDF (141 KB)